REGENXBIO Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RGNX Nasdaq 2836 www.regenxbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for REGENXBIO Inc.

Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas - Jan 20th, 2026 8:06 am
REGENXBIO Inc. (RGNX): A Bull Case Theory - Jan 19th, 2026 3:20 pm
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program - Jan 11th, 2026 1:00 pm
Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says - Jan 6th, 2026 12:45 pm
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 18th, 2025 5:05 am
REGENXBIO to Participate in Upcoming Investor Conference - Nov 25th, 2025 5:05 am
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported And Analysts Are Boosting Their Estimates - Nov 9th, 2025 5:05 am
Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... - Nov 6th, 2025 12:08 pm
Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates - Nov 6th, 2025 6:25 am
Regenxbio: Q3 Earnings Snapshot - Nov 6th, 2025 5:25 am
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights - Nov 6th, 2025 5:05 am
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - Oct 30th, 2025 5:05 am
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights - Oct 29th, 2025 5:05 am
REGENXBIO to Participate in Upcoming Investor Conferences - Oct 15th, 2025 5:05 am
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting - Oct 9th, 2025 5:05 am
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD - Oct 6th, 2025 5:05 am
REGENXBIO Announces Presentation at the World Muscle Society - Sep 29th, 2025 5:05 am
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date - Sep 5th, 2025 11:51 am
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II - Sep 5th, 2025 5:05 am
PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds - Aug 19th, 2025 5:13 am